Pharmaceutical Law & Industry Report® Index-Summary

E-HEALTH

– Electronic prescriptions

– Incentives for MDs, new law studied, 322
– N.M. considers requiring notification of E-health breaches, 184

E-PRESCRIPTIONS

– AMA launches online learning center, 384
– DrFirst to offer through AMA platform, 484
– Incentives sought by community pharmacists, 482
– Medicare

See MEDICARE DRUG COVERAGE

– Regulatory outlook 2009, 80
– State developments

– – Ala. Medicaid system announced, 648
– – CalPERS plans pilot project, 348
– – Governors' group examines, 894
– – Iowa promotes for MDs, 1236
– – Mass. leads states for third year, 746

– Usage reported, 514
– Wider adoption pushed by feds, 1115

EFFEXOR

– Antidepressant blamed for suicide, jury verdict for drug maker upheld (7th Cir.), 230
– Generics

– – Challenged (D. Del.), 437
– – Infringement claimed (D. Del.), 63
– – Summary judgment denied (N.D. W.Va.), 1219

EFFIENT

– Blood clot drug approved, 836; in pharmacies, 926

EFUDEZ

– Dermatological drug, investment firm accused of giving trade secrets to competitor (D. Del.), 523

ELIDEL

– Skin care cream blamed for cancer, suits remanded (D.N.J.), 734

ELOXATIN

– Cancer drug approved, In Brief, 952; approval suspended, 963; approval reinstated, 1001
– Proposed generics no infringement (D.N.J.), 732; stay denied, 822; infringement ruling vacated (Fed. Cir.), 1065; settlement upheld , 1193

EMBEDA

– Pain drug videos, FDA says risks omitted or minimized, 1235

EMEND

– Anti-nausea drug, generic plans challenged (D.N.J.), 284

ENBREL

– Arthritis drug maker accused of illegal marketing (D. Mass.), 255
– Non-infringement ruling affirmed (Fed. Cir.), 635

ENFORCEMENT POLICY

– Clinical trials, HHS IG to review, In Brief, 1175
– Federal Register format changed, 1174

EPOGEN

– Anemia drug off-label promotion, RICO does not apply (C.D. Cal.), 37

ERBITUX

– Cancer drug, FDA wants additional study for first-line squamous cell carcinoma of the head and neck, 270
– Label revision approved by FDA, 870

ERECTILE DYSFUNCTION DRUGS

– Levitra generic challenged (D. Del.), 798
– Switzerland, price-fixing alleged, 214

ERTACZO

– Cream ad inaccuracies, FDA warns maker, 1051

ETHYOL

– Cancer drugs patent dispute settled (D. Md.), 910

ETODOLOC

– Arthritis drug contamination blamed for death, summary judgment granted for maker (E.D. Pa.), 708

EUROPEAN UNION (EU)

See also specific countries
– Antitrust exemption sought by drug firm, 1179
– Cheaper drugs, drug makers suspected of blocking, 813
– Generic drug shipments, action urged to prevent seizures, 240
– Good Clinical Practices Initiative, FDA reaches agreement with EU agency, 919
– Pfizer purchase of Wyeth under scrutiny, 657
– R&D, EU signs off on public-private partnership projects, 628

EVISTA

– Bone-building generic blocked (S.D. Ind.), 1130
– Osteoporosis drug, automatic stay of generic approval upheld (Fed. Cir.), 225
– TRO blocks generic (S.D. Ind.), 281; enjoined, 496

EVOCLIN

– Acne foam maker seeks to block generic (D. Del.), 335

EXJADE

– Iron chelating agent associated with renal failure, 1145

EXPERT WITNESSES

– Accutane suit, expert excluded (M.D. Fla.), 1039
– Diet drug suit, expert disqualified (E.D. Pa.), 825
– Pain pump

– – Deposition of expert ordered (D. Colo.), 914
– – Shoulder joint damage, causation expert excluded (S.D. Fla.), 827

– Seroquel, causation expert witness excluded (Del. Super. Ct.), 734
– Viagra blame for nonarteritic anterior ischemic optic neuropathy, causation expert barred (D. Minn.), 1040
– Zyprexa, causation expert who stretched the truth disqualified (E.D.N.Y.), 587